Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomize
about
Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomize
description
scientific article published on 18 July 2018
@en
name
Pharmacokinetics, pharmacodyna ...... uronidase: A phase 1 randomize
@en
type
label
Pharmacokinetics, pharmacodyna ...... uronidase: A phase 1 randomize
@en
prefLabel
Pharmacokinetics, pharmacodyna ...... uronidase: A phase 1 randomize
@en
P2093
P356
P1476
Pharmacokinetics, pharmacodyna ...... se: A phase 1 randomized trial
@en
P2093
Almasa Bass
Anna Plotka
Catherine Sattler
David R Plowchalk
Khurshid Mridha
P356
10.1002/HSR2.61
P50
P577
2018-07-18T00:00:00Z